Inducible nitric oxide synthase, Nos2, does not mediate optic neuropathy and retinopathy in the DBA/2J glaucoma model
2007

The Role of NOS2 in Glaucoma

Sample size: 362 publication 10 minutes Evidence: moderate

Author Information

Author(s): Libby Richard T, Howell Gareth R, Pang Iok-Hou, Savinova Olga V, Mehalow Adrienne K, Barter Joseph W, Smith Richard S, Clark Abbot F, John Simon WM

Primary Institution: The Jackson Laboratory

Hypothesis

Does NOS2 activity contribute to neurodegeneration in glaucoma?

Conclusion

NOS2 activity is not required for retinal ganglion cell death and associated axon degeneration in DBA/2J mice.

Supporting Evidence

  • NOS2 expression levels varied during different stages of glaucoma.
  • Genetic deficiency of Nos2 did not alter the IOP profile of DBA/2J mice.
  • Neither Nos2 deficiency nor aminoguanidine treatment had any detectable effect on glaucomatous optic nerve damage.

Takeaway

This study found that a specific enzyme, NOS2, doesn't play a role in causing damage in a mouse model of glaucoma, meaning it might not be a good target for treatment.

Methodology

The study involved genetic and pharmacological manipulation of NOS2 in DBA/2J mice, assessing the incidence and severity of glaucoma through various experimental techniques.

Limitations

The study did not assess if other nitric oxide synthases could have compensated for the absence of NOS2.

Participant Demographics

DBA/2J mice, both male and female, were used in the study.

Statistical Information

P-Value

p<0.001

Confidence Interval

95%

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2202-8-108

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication